AGENT FOR INDUCING SPECIFIC IMMUNITY AGAINST SEVERE ACUTE RESPIRATORY SYNDROME VIRUS SARS-COV-2 IN LIQUID FORM (VARIANTS)

The invention relates to a biomolecule agent for inducing specific immunity against severe acute respiratory syndrome virus SARS-CoV-2, in liquid form, which contains a single active component, comprising the expression vector including either: the genome of the recombinant strain of human adenoviru...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Hauptverfasser:	TOKARSKAYA, Elizaveta Alexsandrovna, NARODITSKY, Boris Savelievich, GROUOVA, Daria Mikhailovna, ZUBKOVA, Olga Vadimovna, ESMAGAMBETOV, Ilias Bulatovich, POPOVA, Olga, BORISEVICH, Sergey Vladimirovich, TUKHVATULIN, Amir Ildarovich, TUKHVATULINA, Natalia Mikhailovna, BOTIKOV, Andrei Gennadevich, DZHARULLAEVA, Alina Shahmirovna, IZHAEVA, Fatima Magometovna, SHCHERBININ, Dmitrii Nikolaevich, GINTSBURG, Aleksandr Leonidovich, OZHAROVSKAIA, Tatiana Andreevna, NIKITENKO, Natalya Anatolevna, LOGUNOV, Denis Yuryevich, DOLZHIKOVA, Inna Vadimovna, SHCHEBLIAKOV, Dmitrii Viktorovich, EROXOVA, Alina Sergeevna, SEMIKHIN, Aleksandr Sergeevich, LUBENETS, Nadezhda Leonidovna
Format:	Patent
Sprache:	eng
Schlagworte:	BEER BIOCHEMISTRY CHEMISTRY COMPOSITIONS THEREOF CULTURE MEDIA ENZYMOLOGY HUMAN NECESSITIES HYGIENE MEDICAL OR VETERINARY SCIENCE METALLURGY MICROBIOLOGY MICROORGANISMS OR ENZYMES MUTATION OR GENETIC ENGINEERING ORGANIC CHEMISTRY PEPTIDES PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS SPIRITS VINEGAR WINE
Online-Zugang:	Volltext bestellen
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	The invention relates to a biomolecule agent for inducing specific immunity against severe acute respiratory syndrome virus SARS-CoV-2, in liquid form, which contains a single active component, comprising the expression vector including either: the genome of the recombinant strain of human adenovirus serotype 26 or 5, wherein the E1 and E3 regions are deleted, the vector with an integrated expression cassette is selected from SEQ ID NO:1, SEQ ID NO:2, or SEQ ID NO:3; or the recombinant strain of simian adenovirus serotype 25, wherein the E1 and E3 regions are deleted, the vector with an integrated expression cassette selected from SEQ ID NO:4, SEQ ID NO:2, or SEQ ID NO:3. The recombinant strain of human adenovirus serotype 26 may include the ORF6-Ad26 region replaced by ORF6-Ad5.A buffer solution of the agent in liquid form contains the following, by mass %: tris from 0.1831 to 0.3432; sodium chloride from 0.3313-0.6212; sucrose from 3.7821-7.0915; magnesium chloride hexahydrate from 0.0154-0.0289; EDTA from 0.0029-0.0054; polysorbate-80 from 0.0378-0.0709; ethanol 95% from 0.0004-0.0007; and water to fill.The agent can be administered via intranasal and/or intramuscular routes. The invention promotes humoral and cell-mediated immune responses against SARS-CoV-2 virus among broad strata of the population.